Navigation Links
Comeback of an abandoned antibiotic

This news release is available in German.

The common bacterium Streptococcus pyogenes is responsible not only for scarlet fever, a childhood disease presenting with characteristic skin rash, but also for many suppurative infections of the skin. The infection can be associated with serious consequences such as acute rheumatic fever and inflammation of the kidneys. In Germany, physicians usually prescribe penicillin, an antibiotic. In less-developed countries, penicillin is not always an option though. Firstly, penicillin is often not available and secondly, co-infections, i.e. concurrent infections, by another bacterium called Staphylococcus aureus occur and this microorganism is often no longer susceptible to the action of penicillin.

A group of scientists directed by Dr Patric Nitsche-Schmitz of the HZI entered into cooperation with the German National Reference Center for Streptococci in Aachen, Germany, to investigate if the antibiotic trimethoprim can be helpful in these scenarios. Trimethoprim inhibits an enzyme of folic acid metabolism called dihydrofolate reductase, which plays an important role in bacterial growth. Trimethoprim thus prevents bacteria from proliferating in the body. In the past, doctors advised against the use of this medication for treatment of streptococcal infections. The underlying reasoning was the wide-spread belief that the bacteria are already resistant to this agent, a misconception, as is becoming increasingly more evident. The reason for this mistake is that early studies used a culture medium that reduces the anti-microbial effect of trimethoprim.

The scientists from Braunschweig investigated samples from infected patients from Germany and India for resistance to trimethoprim. The majority of the samples were sensitive to the agent. "This shows that trimethoprim is indeed effective in many cases of Streptococcus pyogenes infection," Nitsche-Schmitz said.

The focus of his team was also on samples, in which the bacteria failed to respond to the agent. They discovered two types of resistance. "Spontaneous mutations can occur in the gene for dihydrofolate reductase rendering trimethoprim no longer able to attack the changed enzyme, which means it becomes ineffective," Nitsche-Schmitz explained. The team from Braunschweig detected a specific mutation in this gene in many samples, which renders streptococci resistant. In addition, bacteria can transfer copies of changed variants of the dihydrofolate reductase gene to other bacteria. This process called horizontal gene transfer allows resistance to spread very rapidly. The scientists found two genes of this type to be further causes of insensitivity.

The study shows that the antibiotic trimethoprim is a therapeutic option for Streptococcus pyogenes infections in some geographical regions of the world. The frequency of resistance is much lower than previously believed and the medication is inexpensive, stable and effective in Staphylococcus aureus co-infections. "However, it is like a sword that can loose its sharpness quickly," Nitsche-Schmitz said. "We found three causes for the rapid spread of resistance. It is important that trimethoprim, like all antibiotics, is not prescribed without need and that patients take the agent in accordance with the instructions given."


Contact: Birgit Manno
Helmholtz Centre for Infection Research

Related biology news :

1. Crowdsourcing to kickstart comeback from ash dieback
2. University of Californias unofficial favorite sea slug poised to make a comeback
3. An extinct frog makes a comeback in Israel
4. Stanford scientists probe abandoned mine for clues about permanent CO2 sequestration
5. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
6. Exposure to antibiotics linked to severity of allergic asthma: UBC research
7. Team discovers how bacteria resist a Trojan horse antibiotic
8. New antibiotic could make food safer and cows healthier
9. Hot on the trail of metabolic diseases and resistance to antibiotics
10. University of Nevada, Reno first to show transgenerational effect of antibiotics
11. Bacteria discovery could lead to antibiotics alternatives
Post Your Comments:
Related Image:
Comeback of an abandoned antibiotic
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... -- Connected health pioneer, Joseph C. Kvedar , MD, ... and wellness, and the business opportunities that arise from ... of Healthy Things . Long before health and ... Kvedar, vice president, Connected Health, Partners HealthCare, was creating ... from the hospital or doctor,s office into the day-to-day ...
(Date:10/27/2015)... 27, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... Google has adopted the Synaptics ® ClearPad ® ... power its newest flagship smartphones, the Nexus 5X by ... --> --> Synaptics works ... strategic collaboration in the joint development of next generation ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... 2015 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... fireside chat discussion at the Piper Jaffray 27th Annual ... The discussion is scheduled for Wednesday, December 2, at ... A replay will be available for 14 days after ... Julie NormartVP, Corporate Communications and Business Development , BrewLife(858) ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology: